Xylos Corporation Awarded U.S. Grant

Xylos Corporation ("Xylos" or the "Company"), a leader in biocellulose technology for medical applications, announced recently that the Company was awarded a grant in the amount of $244,479 under the U.S. Qualifying Therapeutic Discovery Project (QTDP) Program. Xylos' application was focused on its innovative biomaterial solutions for the treatment, repair and replacement of human tissue.

Among various eligibility guidelines, a QTDP applicant was required to demonstrate reasonable potential for its project to result in new therapies to treat areas of unmet medical needs or to prevent, detect, or treat chronic or acute disease and conditions.

Mark S. McNulty, President and CEO of Xylos, commented, "This award is another validation of the scientific importance of our technology and its potential to provide leading care for patients. Funding of this nature is critical to supporting young, innovative companies. In our case, it will facilitate ongoing investment in personnel and research, with the near-term goal of introducing leading-edge implantable devices based on our new class of biomaterial."

About Xylos Corporation
Xylos Corporation, headquartered in Langhorne PA, is a medical device company with a platform technology based on biocellulose. Xylos is dedicated to delivering superior biomaterials solutions for the treatment, repair and replacement of human tissue without the shortfalls associated with tissue harvested from human and animal origins and materials from synthetic sources. Xylos' proprietary biocellulose technology possesses the effectiveness, versatility and safety profile to address a broad range of medical applications including surgical implants for musculoskeletal, urological / gynecological, general, abdominal, cardiovascular and plastic / aesthetics indications representing a market opportunity of over $4B.

SOURCE: Xylos Corporation